T-cell immunotherapy company Atara Biotherapeutics Inc (Nasdaq: ATRA) announced on Wednesday that the U.S. FDA has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel), a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The BLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of 15 January 2025.
If approved, tab-cel would be the first FDA-approved therapy for EBV+ PTLD. The acceptance of the BLA triggers a USD20m milestone payment from Pierre Fabre Laboratories, with an additional USD60m contingent upon FDA approval.
Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA submission is backed by data from over 430 patients, including pivotal ALLELE study results showing a 48.8% Objective Response Rate (ORR) and a favorable safety profile.
The treatment has previously received Breakthrough Therapy Designation and orphan drug status from the FDA. Marketing authorization was granted under the brand name Ebvallo™ by the European Commission in December 2022, the UK Medicines and Healthcare Products Regulatory Agency in May 2023, and Swissmedic in May 2024.
Atara, headquartered in Southern California, leverages its T-cell immunotherapy platform to develop treatments for cancers and autoimmune diseases. The company is the first to receive regulatory approval for an allogeneic T-cell therapy.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment